Just Diagnosed? We Built a Guide for You.
Start with the Newly Diagnosed guide →
Your first steps, what to expect, how to find care in Florida, Ryan White explained, and answers to the questions you're afraid to ask. Built specifically for this moment.
Go to the Guide →When you're ready to go deeper on treatment, this seven-step reading path walks you through everything — from understanding your labs to paying for medications — at your own pace. One thing worth knowing before you start: federal guidelines recommend antiretroviral therapy for everyone living with HIV, regardless of CD4 count, and recommend starting as soon as possible after diagnosis — sometimes the same day.[4]
U=U: Undetectable = Untransmittable
A person living with HIV who is on treatment and maintains an undetectable viral load has zero risk of sexually transmitting HIV to their partners.[1] That is the whole of U=U. Viral suppression is defined as having fewer than 200 copies of HIV per milliliter of blood, and HIV medicine can push the amount of virus so low that a test cannot detect it at all.[3] This is not a reduced risk or a hopeful estimate — and it is one of the strongest reasons to start treatment and stay on it.
HIV Medications
HIV treatment is antiretroviral therapy (ART). Everyone living with HIV should be on it, treatment should start as soon as possible after diagnosis, and pills are the recommended starting point for people just beginning.[2] Before you start, your provider sends a blood sample for genotypic resistance testing — but that test should not delay getting you on medication.[4] Expect a viral load check roughly two to eight weeks after starting or changing a medication, and know that most people get HIV under control within six months.[2] Long-acting options have also arrived: Cabenuva was approved in January 2021 as the first complete extended-release injectable regimen,[7] lenacapavir (Sunlenca) was approved in December 2022 for heavily treatment-experienced adults with multidrug-resistant HIV,[8] and lenacapavir was approved as twice-yearly PrEP under the name Yeztugo in June 2025.[9]
Which Treatment Path Is Right for You?
Answer 3 quick questions and we'll point you toward the treatment approach that fits your life. This is a starting point for a conversation with your provider — not a prescription.
Find your starting point
3 questions. 30 seconds. No personal information collected.
Access & Cost
No one should go without HIV treatment because of cost. These resources cover the major pathways to affordable care — from federal programs to manufacturer assistance. The Ryan White HIV/AIDS Program pays for medical care, medications, and support services for low-income people with HIV, reaches more than half of everyone diagnosed with HIV in the country each year, and is designed to work as a payer of last resort alongside whatever other coverage you have.[17] If you are uninsured, underinsured, or your coverage just changed, your Ryan White case manager is the fastest place to start.
Florida ADAP: where things stand
Florida's AIDS Drug Assistance Program lowered income eligibility from 400% to 130% of the federal poverty level effective March 1, 2026, eliminated insurance premium assistance except for people who are self-insured, and restricted access to certain medications.[18] State lawmakers then appropriated $30.9 million in bridge funding that restored program eligibility at 400% of the federal poverty level through June 30, 2026.[18] The Florida Department of Health's current ADAP criteria list income eligibility at 0–400% of the federal poverty level, and the department states that it is not providing premium assistance at this time.[19] Rules here have changed more than once in a single year — confirm your own eligibility with your Ryan White case manager or ADAP before making any coverage decision. Read the full ADAP breakdown →
HIV & Hepatitis C Coinfection
About 21% of people with HIV in the United States also have hepatitis C.[13] Coinfection matters because untreated hepatitis C can quietly damage the liver over years. Here is the part worth holding onto: hepatitis C can be cured in more than 95% of cases with just 8–12 weeks of well-tolerated, oral-only direct-acting antiviral treatment.[14] Living with HIV does not take that cure off the table — it makes getting screened more important.
Hepatitis C is curable.
If you are living with HIV and have not been tested for hepatitis C — or if you were tested years ago and are at ongoing risk — ask your provider about HCV screening at your next visit. Treatment is 8–12 weeks of oral medication and cures more than 95% of cases.[14] Your HIV status does not prevent you from being cured. Read the full deep dive →
Treatment Deep Dives
Treatment doesn't happen in a vacuum — it happens inside a life that includes aging, other prescriptions, insurance, and everything else. These longer guides go deeper on the parts that shape treatment over time. One reason aging comes up so often: of the more than 1.1 million people living with diagnosed HIV in the United States in 2023, roughly 54% were aged 50 and older.[15]
📖 Browse the Full Deep Dive Library
In-depth guides covering HIV treatment, prevention, history, policy, community, and lived experience. View all deep dives →
Adherence & Side Effects
Modern HIV medicine works because it is taken. The HHS clinical guidelines panel treats adherence as a continuum — something clinicians and patients build together across every visit, not a one-time hurdle at diagnosis.[21] Missed doses can let the virus rebound and, over time, allow resistance mutations to develop that can narrow future options.[5] Most people find a routine that works — a paired-with-coffee habit, a phone alarm, a weekly pill organizer, or moving to a long-acting injectable if pills keep slipping.
Switching Regimens
Being on treatment for a long time does not mean being on the same pills for a long time. The HHS guidelines explicitly cover optimizing therapy in people who are already virally suppressed — simplifying a regimen, moving off older medications with more side effects, cutting pill burden, or switching to a long-acting injectable are all recognized reasons to change.[22] Any switch is planned around your resistance history and current viral load, so bring both to the visit.[5]
Drug Interactions
ART works alongside almost everything else you might take — but there are known interactions that can lower ART levels, raise the other medication's levels, or cause new side effects. The HHS panel maintains the definitive interaction tables used by U.S. HIV providers,[23] and the University of Liverpool's HIV Drug Interactions checker is the widely used bedside reference for looking up individual combinations.[24] Before any new prescription, over-the-counter medication, or supplement, tell the prescriber you are on ART — and if you can, check with your HIV provider or pharmacist too.
Aging with HIV
The HIV population in the United States has been aging for years. Of the more than 1.1 million people living with diagnosed HIV in 2023, roughly 54% were aged 50 and older — a share that keeps growing as effective treatment extends life expectancy.[15] Aging with HIV brings its own care questions: cardiovascular risk, bone density, kidney function, cognition, cancer screening, and how the growing list of non-HIV prescriptions fits alongside ART.
HIV Treatment: True or False?
Now that you know what's available — how much do you know about how it works? Each answer includes the science behind it.
Frequently Asked Questions
A note on this content: The information on this hub covers HIV treatment, medications, lab values, legal rights, and access to care. It is provided for educational purposes only and is not medical or legal advice. HIV treatment decisions, medication changes, and disclosure obligations depend on your individual health situation and applicable laws. Always work with a qualified HIV provider for treatment decisions. For questions about your legal rights — including Florida’s HIV criminalization statutes — consult a legal professional familiar with HIV law. Full disclaimer →
Find HIV Care Near You
Enter your ZIP code — then choose a service below.
References & Sources
Every numbered claim on this page links to the source it came from. We prioritize primary clinical, public-health, and regulatory sources — CDC, the NIH/HHS antiretroviral guidelines panel, NIAID, FDA, HIV.gov, HRSA, and Florida state government for Florida-specific guidance. Guidance and eligibility rules change; when in doubt, check the source and talk with your provider or case manager.
- Centers for Disease Control and Prevention, “Undetectable = Untransmittable” (Global HIV and TB). https://www.cdc.gov/global-hiv-tb/php/our-approach/undetectable-untransmittable.html. ↩a ↩b ↩c
- Centers for Disease Control and Prevention, “HIV Treatment.” https://www.cdc.gov/hiv/treatment/index.html. ↩a ↩b ↩c ↩d ↩e ↩f
- Centers for Disease Control and Prevention, “Starting the Conversation: HIV Treatment as Prevention” (PDF) — viral suppression defined as fewer than 200 copies/mL. https://www.cdc.gov/hivnexus/media/pdfs/2024/04/cdc-hiv-lsht-treatment-brochure-treatment-as-prevention-provider.pdf. ↩a ↩b
- Panel on Antiretroviral Guidelines for Adults and Adolescents (NIH/HHS), “Initiation of Antiretroviral Therapy.” https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/initiation-antiretroviral-therapy. ↩a ↩b
- Panel on Antiretroviral Guidelines for Adults and Adolescents (NIH/HHS), “Laboratory Testing: Drug-Resistance Testing.” https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-resistance-testing. ↩a ↩b ↩c ↩d
- Panel on Antiretroviral Guidelines for Adults and Adolescents (NIH/HHS), “Adverse Effects of Antiretroviral Medications.” https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/adverse-effects-antiretroviral-medications. ↩a ↩b
- HIV.gov, “FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV” (January 22, 2021). https://www.hiv.gov/blog/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv. ↩a ↩b
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, approval package for SUNLENCA (lenacapavir), approval date December 22, 2022 (PDF). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215973,215974Orig1s000Approv.pdf. ↩a ↩b ↩c
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, approval package for YEZTUGO (lenacapavir) for pre-exposure prophylaxis, approval date June 18, 2025 (PDF). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/220020Orig1s000Approv.pdf. ↩a ↩b
- U.S. Food and Drug Administration, “The History of FDA’s Role in Preventing the Spread of HIV/AIDS” — AZT approved March 1987. https://www.fda.gov/about-fda/fda-history-exhibits/history-fdas-role-preventing-spread-hivaids. ↩
- National Institutes of Health, HIVinfo, “The Stages of HIV Infection.” https://hivinfo.nih.gov/understanding-hiv/fact-sheets/stages-hiv-infection. ↩a ↩b
- National Institute of Allergy and Infectious Diseases, “HIV Cure Research.” https://www.niaid.nih.gov/diseases-conditions/hiv-cure-research. ↩
- National Institutes of Health, HIVinfo, “HIV and Hepatitis C.” https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-hepatitis-c. ↩
- Centers for Disease Control and Prevention, “Clinical Care of Hepatitis C.” https://www.cdc.gov/hepatitis-c/hcp/clinical-care/index.html. ↩a ↩b
- HIV.gov, “Aging with HIV.” https://www.hiv.gov/hiv-basics/living-well-with-hiv/taking-care-of-yourself/aging-with-hiv. ↩a ↩b ↩c
- National Institutes of Health, HIVinfo, “Preventing Perinatal Transmission of HIV During Pregnancy and Childbirth.” https://hivinfo.nih.gov/understanding-hiv/fact-sheets/preventing-perinatal-transmission-hiv-during-pregnancy-and-childbirth. ↩
- Health Resources and Services Administration, “Ryan White HIV/AIDS Program — Legislation.” https://ryanwhite.hrsa.gov/about/legislation. ↩
- The Florida Senate, “Senate Introduces Bridge Funding for AIDS Medication” (March 10, 2026) (PDF). https://www.flsenate.gov/PublishedContent/Offices/President/3_10_26_ADAP_Release_and_Remarks_as_Prepared_Combined.pdf. ↩a ↩b
- Florida Department of Health, “AIDS Drug Assistance Program (ADAP)” — eligibility criteria. https://www.floridahealth.gov/diseases-and-conditions/aids/adap/index.html. ↩
- The 2025 Florida Statutes, Chapter 384, “Control of Sexually Transmissible Diseases.” https://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0300-0399/0384/0384.html. ↩
- Panel on Antiretroviral Guidelines for Adults and Adolescents (NIH/HHS), “Adherence to the Continuum of Care.” https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/adherence-continuum-care. ↩
- Panel on Antiretroviral Guidelines for Adults and Adolescents (NIH/HHS), “Optimizing Antiretroviral Therapy in the Setting of Viral Suppression.” https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy. ↩a ↩b
- Panel on Antiretroviral Guidelines for Adults and Adolescents (NIH/HHS), “Drug Interactions.” https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions. ↩a ↩b
- University of Liverpool, “HIV Drug Interactions” (interaction checker). https://www.hiv-druginteractions.org/. ↩